Diplomat Pharmacy, Inc. (NYSE:DPLO) was upgraded by equities research analysts at TheStreet from a “d+” rating to a “c-” rating in a research note issued to investors on Thursday.
Several other analysts also recently commented on DPLO. BidaskClub downgraded shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday. Needham & Company LLC assumed coverage on shares of Diplomat Pharmacy in a report on Friday, July 21st. They set a “buy” rating and a $19.75 price objective for the company. Cowen and Company raised their price objective on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the stock a “market perform” rating in a report on Tuesday, May 9th. Finally, Leerink Swann restated a “market perform” rating and set a $18.00 price objective (up previously from $16.00) on shares of Diplomat Pharmacy in a report on Wednesday, May 17th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus price target of $17.89.
Diplomat Pharmacy (NYSE DPLO) opened at 16.20 on Thursday. The stock’s 50 day moving average is $15.43 and its 200 day moving average is $15.74. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of 88.52 and a beta of 0.66. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $34.80.
Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.23 earnings per share. Analysts predict that Diplomat Pharmacy will post $0.75 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Diplomat Pharmacy, Inc. (DPLO) Upgraded to C- at TheStreet” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/08/12/diplomat-pharmacy-inc-dplo-upgraded-to-c-at-thestreet.html.
A number of hedge funds have recently bought and sold shares of DPLO. JPMorgan Chase & Co. increased its stake in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock worth $116,000 after buying an additional 3,056 shares during the period. State of Alaska Department of Revenue increased its position in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after buying an additional 3,833 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Diplomat Pharmacy by 46.7% in the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after buying an additional 2,794 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Diplomat Pharmacy by 13.8% in the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after buying an additional 1,073 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in Diplomat Pharmacy during the first quarter valued at $160,000. Institutional investors and hedge funds own 72.02% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
What are top analysts saying about Diplomat Pharmacy Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Diplomat Pharmacy Inc. and related companies.